Share on StockTwits

Theravance (NASDAQ:THRX) has been given an average rating of “Hold” by the nine ratings firms that are presently covering the stock, American Banking and Market News reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $29.60.

Shares of Theravance (NASDAQ:THRX) traded down 1.93% on Thursday, hitting $25.8899. The stock had a trading volume of 396,903 shares. Theravance has a one year low of $20.2337 and a one year high of $34.6172. The stock has a 50-day moving average of $22.67 and a 200-day moving average of $26.80. The company’s market cap is $2.916 billion.

Theravance (NASDAQ:THRX) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.62) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.53) by $0.09. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $4.52 million. During the same quarter last year, the company posted ($0.39) earnings per share. Theravance’s revenue was down 87.3% compared to the same quarter last year. Analysts expect that Theravance will post $-1.44 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Citigroup Inc. downgraded shares of Theravance from a “buy” rating to a “hold” rating in a research note on Thursday. Separately, analysts at Stifel downgraded shares of Theravance from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, analysts at Stifel Nicolaus downgraded shares of Theravance from a “buy” rating to a “hold” rating in a research note on Thursday. They now have a $47.00 price target on the stock, up previously from $37.86. They noted that the move was a valuation call.

Theravance, Inc (NASDAQ:THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.